Cargando…

Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis

To investigate the clinical characteristics, treatments and prognosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 tRCC), the epidemiological features and treatment results of 34 cases of Xp11.2 tRCC, which were diagnosed by immunohistochemistry staining of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ning, Wang, Zhen, Gan, Weidong, Xiong, Lei, Miao, Baolei, Chen, Xiancheng, Guo, Hongqian, Li, Dongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125634/
https://www.ncbi.nlm.nih.gov/pubmed/27893792
http://dx.doi.org/10.1371/journal.pone.0166897
_version_ 1782469991883341824
author Liu, Ning
Wang, Zhen
Gan, Weidong
Xiong, Lei
Miao, Baolei
Chen, Xiancheng
Guo, Hongqian
Li, Dongmei
author_facet Liu, Ning
Wang, Zhen
Gan, Weidong
Xiong, Lei
Miao, Baolei
Chen, Xiancheng
Guo, Hongqian
Li, Dongmei
author_sort Liu, Ning
collection PubMed
description To investigate the clinical characteristics, treatments and prognosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 tRCC), the epidemiological features and treatment results of 34 cases of Xp11.2 tRCC, which were diagnosed by immunohistochemistry staining of TFE3 and fluorescence in situ hybridization at our center, were retrospectively reviewed. The 34 patients included 21 females and 13 males aged 3 to 64 years (median age: 27 years). Four patients were children or adolescents (<18 years of age), and 26 patients were young or middle-aged adults (18–45 years). Radical nephrectomy was performed on 25 patients. Laparoscopic nephron-sparing surgery was performed on 9 patients who presented with an isolated mass with a small diameter (<7 cm) and well-defined boundary on computed tomography imaging. Postoperative staging showed that 25 cases (73.53%) were at stage I/II, while 9 cases (26.47%) were at stage III/IV. All stage I/II patients received a favorable prognosis with a three-year overall survival rate of 100%, including the patients who underwent laparoscopic nephron-sparing surgery. With the exception of 2 children, the other 7 stage III/IV patients died or developed recurrence with a median follow-up of 29 months. On univariate analysis, maximum diameter, adjuvant treatment, TNM stage, lymph node metastasis, inferior vena cava tumor thrombosis and tumor boundary were identified as statistically significant factors impacting survival (P<0.05). Multivariate analysis indicated that TNM stage and inferior vena cava tumor thrombosis were independent prognostic factors (P<0.05). In conclusion, Xp11.2 tRCC is a rare subtype of renal cell carcinoma that mainly occurs in young females. Nephron-sparing surgery was confirmed effective preliminarily in the treatment of small Xp11.2 tRCCs with clear rims. Advanced TNM stage and inferior vena cava tumor thrombosis were associated with poor prognosis.
format Online
Article
Text
id pubmed-5125634
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-51256342016-12-15 Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis Liu, Ning Wang, Zhen Gan, Weidong Xiong, Lei Miao, Baolei Chen, Xiancheng Guo, Hongqian Li, Dongmei PLoS One Research Article To investigate the clinical characteristics, treatments and prognosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 tRCC), the epidemiological features and treatment results of 34 cases of Xp11.2 tRCC, which were diagnosed by immunohistochemistry staining of TFE3 and fluorescence in situ hybridization at our center, were retrospectively reviewed. The 34 patients included 21 females and 13 males aged 3 to 64 years (median age: 27 years). Four patients were children or adolescents (<18 years of age), and 26 patients were young or middle-aged adults (18–45 years). Radical nephrectomy was performed on 25 patients. Laparoscopic nephron-sparing surgery was performed on 9 patients who presented with an isolated mass with a small diameter (<7 cm) and well-defined boundary on computed tomography imaging. Postoperative staging showed that 25 cases (73.53%) were at stage I/II, while 9 cases (26.47%) were at stage III/IV. All stage I/II patients received a favorable prognosis with a three-year overall survival rate of 100%, including the patients who underwent laparoscopic nephron-sparing surgery. With the exception of 2 children, the other 7 stage III/IV patients died or developed recurrence with a median follow-up of 29 months. On univariate analysis, maximum diameter, adjuvant treatment, TNM stage, lymph node metastasis, inferior vena cava tumor thrombosis and tumor boundary were identified as statistically significant factors impacting survival (P<0.05). Multivariate analysis indicated that TNM stage and inferior vena cava tumor thrombosis were independent prognostic factors (P<0.05). In conclusion, Xp11.2 tRCC is a rare subtype of renal cell carcinoma that mainly occurs in young females. Nephron-sparing surgery was confirmed effective preliminarily in the treatment of small Xp11.2 tRCCs with clear rims. Advanced TNM stage and inferior vena cava tumor thrombosis were associated with poor prognosis. Public Library of Science 2016-11-28 /pmc/articles/PMC5125634/ /pubmed/27893792 http://dx.doi.org/10.1371/journal.pone.0166897 Text en © 2016 Liu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Liu, Ning
Wang, Zhen
Gan, Weidong
Xiong, Lei
Miao, Baolei
Chen, Xiancheng
Guo, Hongqian
Li, Dongmei
Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis
title Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis
title_full Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis
title_fullStr Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis
title_full_unstemmed Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis
title_short Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis
title_sort renal cell carcinoma associated with xp11.2 translocation/tfe3 gene fusions: clinical features, treatments and prognosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125634/
https://www.ncbi.nlm.nih.gov/pubmed/27893792
http://dx.doi.org/10.1371/journal.pone.0166897
work_keys_str_mv AT liuning renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis
AT wangzhen renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis
AT ganweidong renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis
AT xionglei renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis
AT miaobaolei renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis
AT chenxiancheng renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis
AT guohongqian renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis
AT lidongmei renalcellcarcinomaassociatedwithxp112translocationtfe3genefusionsclinicalfeaturestreatmentsandprognosis